Return to Clinical Trials Search Results

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Primary objective To compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients. Secondary objectives 1.To compare the effect of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients upon: 1.Distant disease-free survival 2.Overall survival 3.Cardiovascular disease (see Section11.3) 2.To compare the toxicity of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients. 3.To assess adherence to aspirin and placebo among early stage node-positive HER2 negative breast cancer patients. 4.To bank tumor and germline deoxyribonucleic acid (DNA), plasma and urine collected at baseline and sequential plasma and urine collected 2 years later for future measurement of inflammatory markers. 5.To determine if there are subgroups of participants characterized by lifestyle factors associates with greater inflammation for whom there is greater benefit of aspirin versus placebo upon iDFS.

Primary objective To compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients. Secondary objectives 1.To compare the effect of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients upon: 1.Distant disease-free survival 2.Overall survival 3.Cardiovascular disease (see Section11.3) 2.To compare the toxicity of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients. 3.To assess adherence to aspirin and placebo among early stage node-positive HER2 negative breast cancer patients. 4.To bank tumor and germline deoxyribonucleic acid (DNA), plasma and urine collected at baseline and sequential plasma and urine collected 2 years later for future measurement of inflammatory markers. 5.To determine if there are subgroups of participants characterized by lifestyle factors associates with greater inflammation for whom there is greater benefit of aspirin versus placebo upon iDFS.